Catecholamines are compounds that function as neurotransmitters and hormones in various physiological processes. The class of endogenous catecholamines includes dopamine, norepinephrine, and epinephrine. These molecules have key roles in mediating the sympathetic nervous response and several neurologic pathways. Additionally, excess or deficient amounts of free catecholamines are associated with several psychiatric and medical conditions. Therefore, the mechanism of catecholamine degradation, and conditions that result in such dysfunction of that system, are of interest in the study of medicine. This article provides an overview of catecholamine degradation mechanisms as well as their clinical correlations.
Mechanism of catecholamine degradation:
Please see the attached figure for a pictorial overview of the following steps:
Step 1: Deamination catalyzed by monoamine oxidase (MAO):
Forms deaminated aldehyde intermediates.
Dopamine converted to 3,4-dihydroxy phenylacetaldehyde (DOPAL)
Norepinephrine and epinephrine both convert to 3,4-dihydroxy phenyl glycolaldehyde (DOPEGAL)
Step 2: Formation of alcohol or acid metabolites:
Two main enzymes are aldehyde dehydrogenase (AD) and aldehyde reductase (AR)
AD works to convert DOPAL to 3,4-dihydroxyphenylacetic acid (DOPAC) and DOPEGAL to 3,4-dihydroxymethamphetamine (DHMA)
AR works to convert DOPAL to 34-dihydroxy phenyl ethanol (DOPET) and DOPEGAL to 3,4-dihydroxy phenyl glycol (DHPG)
Because dopamine and DOPAL both lack a beta-hydroxyl group, DOPAL will preferentially bind to AD, favoring DOPAC formation.
Because epinephrine, norepinephrine, and DOPEGAL all have a beta-hydroxyl group, DOPEGAL will preferentially bind AR, favoring the formation of DHPG.
In sympathetic neurons and chromaffin cells, a third enzyme called aldose reductase also converts DOPEGAL to DHPG (not shown)
Primary dopamine metabolite DOPAC is converted to homovanillic acid (HVA), which is the end-product of dopamine degradation.
The primary metabolite of norepinephrine and epinephrine DHPG converted to vanylglycol (MHPG)
Note: COMT can also convert norepinephrine to normetanephrine, which is converted to 3-hydroxy-4-hydroxyphenyl glycolaldehyde (MOPEGAL) by MAO (red pathway in the figure)
Step 4: Formation of vanillylmandelic acid (VMA):
Catalyzed by acetaldehyde dehydrogenase
MHPG converted to MOPEGAL (short-lived intermediate)
MOPEGAL converted to VMA, end-product of epinephrine and norepinephrine degradation
Locations of Degradation
Epinephrine and norepinephrine primarily get synthesized in sympathetic neurons or the adrenal medulla.
Within sympathetic neurons, the production of epinephrine and norepinephrine is in storage vesicles released on neuronal activation. While in storage, catecholamines can passively leak into the neuronal cytoplasm and undergo deamination by intracellular monoamine oxidase. Therefore, the initial step of catecholamine degradation mostly takes place inside the synthesizing cell. A smaller amount of deamination by MAO takes place in the extracellular space.
COMT, in contrast, is not contained within sympathetic nerve cells. Therefore, all steps in the degradation pathway that require COMT take place outside the neuron. This activity could be in the extracellular space or within other cells, such as chromaffin cells in the adrenal medulla. Chromaffin cells contain both MAO and COMT. Therefore, the complete degradation of norepinephrine or epinephrine to VMA can occur within chromaffin cells.
Dopamine gets produced by several cell types, most commonly dopaminergic neurons in discrete areas of the brain and mesenteric organ cells. Dopamine metabolism and the formation of HVA occur in the extracellular space, most often before reaching the liver.
Norepinephrine, epinephrine, and all of their intermediate metabolites from degradation eventually travel to the liver, where they are extracted and converted to end product VMA, which ultimately gets eliminated by the kidneys. HVA, which typically forms outside the liver, also undergoes renal elimination by the kidneys and is generally excreted twice as fast as VMA.
Catecholamines function in several vital neurological and physiological systems. The proper functioning of these systems requires an appropriate balance in synthesis and degradation. When degradation is impaired, this leads to the hyperfunctioning of these systems.
In the central nervous system, dopamine is the principal activator of four major pathways in the brain. The nigrostriatal pathway starts from the substantia nigra and connects to the basal ganglia. Activation of the neurons in this pathway is responsible for movement and sensory stimuli. The mesolimbic pathway starts in the ventral tegmental area and goes to the amygdala, pyriform cortex, and nucleus accumbens. Neurons in this pathway are responsible for emotion, pleasure and reward-seeking, addiction, and perception. The mesocortical pathway starts in the ventral tegmental area and goes to the frontal cortex and hippocampus. This pathway is responsible for cognition, memory, and attention. Finally, the tuberoinfundibular system starts in the arcuate nucleus of the hypothalamus and goes to the median eminence of the pituitary gland. This pathway functions to inhibit prolactin secretion from the pituitary gland. In the periphery, dopamine functions as a vasodilator that mainly affects the kidney, promoting diuresis and natriuresis.
Epinephrine and norepinephrine have similar functions as part of the sympathetic nervous system. They differ slightly in that norepinephrine exclusively acts on arteries, whereas epinephrine can bind to receptors on arteries, the heart, lungs, and skeletal muscles. Together, these hormones mediate the sympathetic nervous response leading to tachycardia, increased cardiac contractility, hyperglycemia, and relaxation of smooth muscle in the lungs. Norepinephrine is also primarily responsible for arterial vasoconstriction, leading to increased blood pressure.
Catecholamines are involved in a multitude of physiologic processes and pathology. The following are a few of many examples where knowledge of the degradation pathways has clinical significance.
Parkinson disease is associated with insufficient dopamine in the nigrostriatal pathway. When pharmacological therapy is necessary, one option is a class of drugs called MAO-B inhibitors. These drugs inhibit the initial step of dopamine degradation and increase dopamine levels in the extracellular space. An additional class of drugs, sometimes used with exogenous dopamine therapy, is COMT inhibitors. Similarly, these drugs decrease the rate of dopamine degradation.
Schizophrenia, as opposed to Parkinson disease, is associated with excess dopamine. The primary treatment is with D2 receptor blockers. A medication formerly used in treatment was reserpine. This agent blocked the storage of produced catecholamines into vesicles, thereby increasing the rate of intracellular degradation. This drug is no longer used for this purpose because of a significant side-effect profile, especially with older individuals.
Pheochromocytomas are adrenal medullary tumors associated with the production of large amounts of catecholamines. They can manifest as episodes of tachycardia, hypertension, and headache. The diagnosis of pheochromocytomas and other catecholamine-producing tumors requires detecting metabolites HVA and VMA in the plasma and urine.
(Click Image to Enlarge)
Created and contributed by Sarah Kamal
Vlachakis ND,Alexander N,Velasquez MT,Maronde RF, A radioenzymatic microassay for simultaneous measurement of catecholamines and their deaminated metabolites. Biochemical medicine. 1979 Dec; [PubMed PMID: 43728]
Roth JA, Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Reviews of physiology, biochemistry and pharmacology. 1992; [PubMed PMID: 1519017]
Blombery PA,Kopin IJ,Gordon EK,Markey SP,Ebert MH, Conversion of MHPG to vanillylmandelic acid. Implications for the importance of urinary MHPG. Archives of general psychiatry. 1980 Oct; [PubMed PMID: 7425794]
Chahine R,Nadeau R,Lamontagne D,Yamaguchi N,de Champlain J, Norepinephrine and dihydroxyphenylglycol effluxes from sympathetic nerve endings during hypoxia and reoxygenation in the isolated rat heart. Canadian journal of physiology and pharmacology. 1994 Jun; [PubMed PMID: 7954091]
Raber W,Raffesberg W,Bischof M,Scheuba C,Niederle B,Gasic S,Waldhäusl W,Roden M, Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Archives of internal medicine. 2000 Oct 23; [PubMed PMID: 11041903]
Sawka AM,Jaeschke R,Singh RJ,Young WF Jr, A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. The Journal of clinical endocrinology and metabolism. 2003 Feb; [PubMed PMID: 12574179]
Brown MJ, Simultaneous assay of noradrenaline and its deaminated metabolite, dihydroxyphenylglycol, in plasma: a simplified approach to the exclusion of phaeochromocytoma in patients with borderline elevation of plasma noradrenaline concentration. European journal of clinical investigation. 1984 Feb; [PubMed PMID: 6421600]
Use the mouse wheel to zoom in and out, click and drag to pan the image